Skip to main content

Peer Review reports

From: Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion

Original Submission
12 Oct 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
30 Nov 2022 Reviewed Reviewer Report - Kevin R. Lynch
9 Dec 2022 Reviewed Reviewer Report
16 Dec 2022 Reviewed Reviewer Report
20 Apr 2023 Author responded Author comments - Anne Régnier-Vigouroux
Resubmission - Version 4
20 Apr 2023 Submitted Manuscript version 4
3 May 2023 Author responded Author comments - Anne Régnier-Vigouroux
Resubmission - Version 5
3 May 2023 Submitted Manuscript version 5
4 May 2023 Author responded Author comments - Anne Régnier-Vigouroux
Resubmission - Version 6
4 May 2023 Submitted Manuscript version 6
23 Jun 2023 Reviewed Reviewer Report
3 Jul 2023 Reviewed Reviewer Report
4 Aug 2023 Author responded Author comments - Anne Régnier-Vigouroux
Resubmission - Version 7
4 Aug 2023 Submitted Manuscript version 7
Publishing
7 Aug 2023 Editorially accepted
16 Aug 2023 Article published 10.1186/s12885-023-11271-w

You can find further information about peer review here.

Back to article page